Bringing DNA repair in tumors into focus.
Biomarkers are of crucial importance in optimizing cancer therapies. In this edition of Clinical Cancer Research, Bañuelos and colleagues assess H2AX phosphorylation as a predictive biomarker of response to DNA damaging agents. We discuss these results as well as the impact that double strand break repair biomarkers may have in cancer therapy.
Lord
Christopher J
CJ
The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK. Chris.Lord@icr.ac.uk
Ashworth
Alan
A
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D053903:DNA Breaks, Double-Stranded; D004260:DNA Repair; D019583:Dose Fractionation, Radiation; D005434:Flow Cytometry; D006657:Histones / Q000096:biosynthesis*; D006801:Humans; D051379:Mice; D008856:Microscopy, Fluorescence; D008954:Models, Biological; D009374:Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D010766:Phosphorylation / Q000187:drug effects / Q000528:radiation effects; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; C468783:H2AX protein, human; D006657:Histones; D002945:Cisplatin